1 results match your criteria: "Heersink School of Medicine at the University of Alabama at Birmingham (UAB-SOM)[Affiliation]"
HiJAKing Immunotherapy-Resistant Melanoma for a Cure.
Oncologist
March 2023
Department of Radiation Oncology, Heersink School of Medicine at the University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.
Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors concerning ICB resistance in melanoma patients.
View Article and Find Full Text PDF